RefleXion to Present at 2024 Jeffries Global Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)-- RefleXion Medical, Inc., a theranostic external-beam radiotherapy company, today announced that Todd Powell, president and chief executive officer, Sam Mazin, Ph.D., founder and chief technology officer, and Sean Shirvani, M.D., chief medical officer will present an overview of the company and its breakthrough SCINTIX biology-guided radiotherapy at the Jeffries Global Healthcare Conference on Wednesday, June 5 at 8:30 a.m. EDT.

About RefleXion Medical

RefleXion is a privately held therapeutic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel therapy that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors arising from either primary lung and bone cancers or resulting from metastases by other primary cancers. In addition to SCINTIX therapy, the RefleXion X1 is also FDA-cleared for conventional image-guided external-beam radiotherapy for solid tumors located anywhere in the body. For more information, please visit www.reflexion.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604872330/en/

RefleXion Contact:
Amy Cook
[email protected]
+1 925-222-5094

Source: RefleXion Medical, Inc.

You May Also Be Interested In

• Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
• Bitcoin Price Prediction: $1.1B ETF Week Rebuilds Institutional Demand as AlphaPepe Targets the Wider Pre-Chart Upside Window
• Lyt Inc. Launches LytSpace: Genome AI Configures Over 150 Sensors Autonomously, While Full-Resolution Biometric Data Is Preserved for Decades